Trial
NCT05866926
Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Ferrer Internacional S.A.
Collaborators
—
Condition
Amyotrophic Lateral Sclerosis
Intervention
FAB122
Why stopped
After the analysis of the main ADORE study it is concluded that there is no clinical benefit for the patients.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-04